< Back to previous page

Publication

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival (vol 32, pg 1015, 2021)

Journal Contribution - Journal Article

Journal: Annals Of Oncology
ISSN: 0923-7534
Issue: 10
Volume: 32
Pages: 1307 - 1307
Publication year:2021
Accessibility:Open